FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W3020635237> ?p ?o ?g. }

• W3020635237 abstract "Background Peripartum cardiomyopathy is a rare, pregnancy associated cause of left ventricular heart failure in previously healthy women. It remains an important cause of cardiac-related maternal morbidity and mortality worldwide. Half of the patients will recover left ventricular function after 6 months. However, in the remainder of patients who do not recover cardiac function, they will require advanced heart failure therapies. Bromocriptine, a dopamine agonist which inhibits prolactin release, has demonstrated improvement in left ventricular recovery and clinical outcome. We sought to determine the effect of adding Bromocriptine to standard heart failure therapy on the improvement and recovery of left ventricular function and cardiovascular mortality of these patients. Inclusion Criteria. Studies were included if they satisfied the following criteria:1) Randomized Controlled Trials; 2) Pregnant patients who fulfilled the criteria for diagnosis of peripartum cardiomyopathy and 3) Reported data on improvement in left ventricular ejection fraction and clinical outcomes. Methods. Using PUBMED, Clinical Key, Science Direct, Scopus, and Cochrane databases, a search for eligible studies was conducted from June to December 31, 2018. The quality of each study was evaluated using the Cochrane Risk of Bias Tool. The primary outcome of interest is on the effect of Bromocriptine on the improvement of left ventricular function and clinical outcomes among these patients. Review Manager 5.3 was utilized to perform analysis of random effects for continuous outcomes. Results. We identified 2 randomized controlled trials of 116 pregnant patients diagnosed with peripartum cardiomyopathy, showing that among those who received Bromocriptine on top of standard heart failure therapy, there is a significant improvement in the left ventricular ejection fraction at 6 months [mean difference 15.14 (95% CI, 6.53 to 23.75) p <0.05] compared to standard heart failure therapy alone. It was also observed that those who received Bromocriptine had better clinical outcomes. Conclusion. The addition of Bromocriptine on top of standard heart failure therapy significantly improved the left ventricular ejection fraction of patients with peripartum cardiomyopathy at 6-months post-partum. This novel therapy may be considered to improve the management of these patients." @default.
• W3020635237 created "2020-05-01" @default.
• W3020635237 creator A5024339594 @default.
• W3020635237 creator A5031904620 @default.
• W3020635237 creator A5044956140 @default.
• W3020635237 creator A5088184328 @default.
• W3020635237 date "2020-01-01" @default.
• W3020635237 modified "2023-09-25" @default.
• W3020635237 title "Use of Bromocriptine for the Treatment of Peripartum Cardiomyopathy: A Meta-Analysis of Randomized Controlled Trials" @default.
• W3020635237 doi "https://doi.org/10.11648/j.ccr.20200402.14" @default.
• W3020635237 hasPublicationYear "2020" @default.
• W3020635237 type Work @default.
• W3020635237 sameAs 3020635237 @default.
• W3020635237 citedByCount "0" @default.
• W3020635237 crossrefType "journal-article" @default.
• W3020635237 hasAuthorship W3020635237A5024339594 @default.
• W3020635237 hasAuthorship W3020635237A5031904620 @default.
• W3020635237 hasAuthorship W3020635237A5044956140 @default.
• W3020635237 hasAuthorship W3020635237A5088184328 @default.
• W3020635237 hasBestOaLocation W30206352371 @default.
• W3020635237 hasConcept C126322002 @default.
• W3020635237 hasConcept C164705383 @default.
• W3020635237 hasConcept C168563851 @default.
• W3020635237 hasConcept C2776856834 @default.
• W3020635237 hasConcept C2778198053 @default.
• W3020635237 hasConcept C2778490853 @default.
• W3020635237 hasConcept C2778797674 @default.
• W3020635237 hasConcept C2779064019 @default.
• W3020635237 hasConcept C71315377 @default.
• W3020635237 hasConcept C71924100 @default.
• W3020635237 hasConcept C78085059 @default.
• W3020635237 hasConceptScore W3020635237C126322002 @default.
• W3020635237 hasConceptScore W3020635237C164705383 @default.
• W3020635237 hasConceptScore W3020635237C168563851 @default.
• W3020635237 hasConceptScore W3020635237C2776856834 @default.
• W3020635237 hasConceptScore W3020635237C2778198053 @default.
• W3020635237 hasConceptScore W3020635237C2778490853 @default.
• W3020635237 hasConceptScore W3020635237C2778797674 @default.
• W3020635237 hasConceptScore W3020635237C2779064019 @default.
• W3020635237 hasConceptScore W3020635237C71315377 @default.
• W3020635237 hasConceptScore W3020635237C71924100 @default.
• W3020635237 hasConceptScore W3020635237C78085059 @default.
• W3020635237 hasLocation W30206352371 @default.
• W3020635237 hasOpenAccess W3020635237 @default.
• W3020635237 hasPrimaryLocation W30206352371 @default.
• W3020635237 hasRelatedWork W13846486 @default.
• W3020635237 hasRelatedWork W14519780 @default.
• W3020635237 hasRelatedWork W18801412 @default.
• W3020635237 hasRelatedWork W4282694 @default.
• W3020635237 hasRelatedWork W4535602 @default.
• W3020635237 hasRelatedWork W655351 @default.
• W3020635237 hasRelatedWork W6628010 @default.
• W3020635237 hasRelatedWork W6856088 @default.
• W3020635237 hasRelatedWork W9486501 @default.
• W3020635237 hasRelatedWork W15042919 @default.
• W3020635237 isParatext "false" @default.
• W3020635237 isRetracted "false" @default.
• W3020635237 magId "3020635237" @default.
• W3020635237 workType "article" @default.